December 2021

The Covid-19 pandemic has highlighted more clearly than ever the need for security and traceability at every step of the drug supply chain.


In the next issue of Pharma Technology Focus we look at how digitising the pharma supply chain – and utilising blockchain technology – can ensure medicines travel from manufacturer to patient with greater visibility and security, and reduce the risk of counterfeit drugs entering supplies.


Also, for patients that are struggling to get hold of vital medical because of supply chain issues or are left without legally approved medications due to political rulings, the dark web can be a tempting – if risky – solution.


To find out why illegal online pharmacies have become a final resort, we talk to some of those impacted by drug shortages, and the companies that are having to compete with illegal trade.

EDITORIAL

Editor | Eloise McLennan

Writers | Abi Millar, Darcy Jimenez, Kezia Parkins
Magazine Designer | Maria Gimenez

Graphic Designers | Anett Arc, Ashley McPherson, Tyrrell Lowe, Noemi Balint, Filipe Costa, Martina Labaiova, Dimeji Akinkuolie, Will Ingham​​​​​​​
Lead Designer | John Hammond 

Publisher | Susanne Hauner
Digital Publishing Director | Duncan West

Advertising

Sales Manager | Nimai Amin

+44 (0) 207 936 6453

Pharma Technology focus is powered by h5mag

read past issues of pharma technology focus HERE

Copyright 2021 NRi Digital, a trading division of Verdict Media Ltd. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.

Go to article: Home | Unpacking innovation in biologics Go to article: In this issueGo to article: ContentsGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: Verder Company InsightGo to article: VerderGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Controlant Company InsightGo to article: ControlantGo to article: DatwylerGo to article: BaxterGo to article: CommentGo to article: Novel therapies will drive Cushing’s syndrome market growthGo to article: Interim analysis backs Keytruda use in first-line cervical cancer therapy Go to article: Unmet needs and opportunities for axillary hyperhidrosisGo to article: Pfeiffer VacuumGo to article: HOF SonderanlagenbauGo to article: Avery Dennison Company Insight Go to article: Avery DennisonGo to article: In DepthGo to article: The reality of optimising real-world data Go to article: The ethics of vaccine boostersGo to article: Forever young: can science cure ageing? Go to article: Predicting the placebo responseGo to article: US regulators struggle to keep up with a global marketGo to article: BCG: the history and modern-day uses of the tuberculosis vaccineGo to article: BEA TechnologiesGo to article: MyonexGo to article: Contract Pharmaceuticals Limited CanadaGo to article: Single Use SupportGo to article: SkyepharmaGo to article: In DataGo to article: Cloud hiring effortsGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article: Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue